Cibus (NASDAQ:CBUS – Get Free Report) released its earnings results on Thursday. The company reported ($0.33) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.06), FiscalAI reports. The firm had revenue of $1.68 million during the quarter, compared to analyst estimates of $1.61 million. Cibus had a negative return on equity of 186.68% and a negative net margin of 2,366.33%.
Here are the key takeaways from Cibus’ conference call:
- Cibus said its top priority in 2026 is commercial execution, with momentum building across rice and sustainable ingredients and more customer conversations moving closer to revenue.
- In rice, the company reported progress with Interoc, including a non-binding LOI, additional import permits, and delivery of gene-edited material, supporting its planned 2027 Latin America launch.
- The company pushed its U.S. rice launch timeline from 2028 to 2029 because herbicide registration work with partner Orbar/Alba is running behind the original schedule.
- Sustainable ingredients appears to be ramping, with Cibus describing the program as in a commercial ramp-up phase, expecting additional biofragrance scale-up orders in the second half of 2026 and ongoing work on soybean lauric oils.
- Financially, Cibus ended the quarter with $30.3 million in cash after raising about $37 million in two offerings, and management expects cash to fund operations into late Q1 2027 while targeting annual net cash usage of $30 million or less.
Cibus Price Performance
Shares of NASDAQ:CBUS traded down $0.10 on Friday, reaching $1.31. 342,064 shares of the company traded hands, compared to its average volume of 390,337. Cibus has a fifty-two week low of $1.09 and a fifty-two week high of $4.19. The company’s 50 day moving average is $2.08 and its 200-day moving average is $1.97. The stock has a market capitalization of $100.02 million, a PE ratio of -0.66 and a beta of 1.66. The company has a debt-to-equity ratio of 1.37, a current ratio of 0.72 and a quick ratio of 0.72.
Cibus News Roundup
- Positive Sentiment: Cibus’ Q1 revenue of $1.68 million topped analyst estimates, showing some business momentum despite ongoing losses. Cibus earnings report
- Neutral Sentiment: Management issued a business update and said the company has runway into late Q1 2027, which may reassure investors about near-term liquidity. Seeking Alpha business update
- Negative Sentiment: Cibus reported an adjusted quarterly loss of $0.33 per share, missing the consensus estimate of a $0.27 loss, reinforcing concerns about profitability. Zacks earnings note
- Negative Sentiment: Sidoti cut EPS estimates for several periods, including FY2026 to a loss of $1.45 per share and FY2027 to a loss of $1.14 per share, signaling a more cautious outlook. Cibus earnings call transcript
Analysts Set New Price Targets
A number of equities research analysts have weighed in on CBUS shares. Weiss Ratings restated a “sell (e+)” rating on shares of Cibus in a research report on Wednesday, January 21st. Jefferies Financial Group upped their target price on Cibus from $1.90 to $3.00 and gave the stock a “hold” rating in a research report on Wednesday, March 25th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $9.00.
View Our Latest Report on CBUS
Institutional Investors Weigh In On Cibus
A number of institutional investors and hedge funds have recently modified their holdings of the stock. Geode Capital Management LLC lifted its position in shares of Cibus by 4.7% during the 4th quarter. Geode Capital Management LLC now owns 275,180 shares of the company’s stock valued at $479,000 after acquiring an additional 12,467 shares during the last quarter. Jane Street Group LLC acquired a new stake in shares of Cibus during the 2nd quarter valued at $207,000. Corient Private Wealth LLC acquired a new stake in shares of Cibus during the 4th quarter valued at $145,000. Renaissance Technologies LLC lifted its position in shares of Cibus by 74.4% during the 4th quarter. Renaissance Technologies LLC now owns 69,400 shares of the company’s stock valued at $121,000 after acquiring an additional 29,600 shares during the last quarter. Finally, Raymond James Financial Inc. lifted its position in shares of Cibus by 31.0% during the 2nd quarter. Raymond James Financial Inc. now owns 53,713 shares of the company’s stock valued at $74,000 after acquiring an additional 12,722 shares during the last quarter. Institutional investors and hedge funds own 33.81% of the company’s stock.
About Cibus
Cibus, Inc is a biotechnology company specializing in precision gene editing for agricultural applications. Leveraging its proprietary Rapid Trait Development System (RTDS), Cibus develops improved crop traits without the introduction of foreign DNA. The company’s platform enables targeted modifications to plant genomes, allowing for enhanced disease resistance, herbicide tolerance and yield optimization in key row crops.
The company’s core business centers on trait development services and licensing partnerships.
Read More
- Five stocks we like better than Cibus
- 3 Crucial Aerospace Component Makers That Analysts Love
- Alphabet’s Googlebook Brings Gemini AI to PC Hardware
- Peloton Stock Gives Back Gains After Upbeat Earnings Report
- MarketBeat Week in Review – 05/11 – 05/15
Receive News & Ratings for Cibus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cibus and related companies with MarketBeat.com's FREE daily email newsletter.
